Who Paid My Doc
Thymoglobulin
Biological Oncology
NDC 58468-0080-1
General payments
$3,049,532
Research payments
$4,069,464
Through program year 2025, $3,049,532 in general payments and $4,069,464 in research payments were reported against Thymoglobulin (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $598,649 | 596 |
| 2025 | Research | $1,708,080 | 8 |
| 2024 | General | $736,930 | 548 |
| 2024 | Research | $1,815,506 | 7 |
| 2023 | General | $534,335 | 494 |
| 2023 | Research | $90,101 | 1 |
| 2022 | General | $563,514 | 418 |
| 2021 | General | $290,659 | 256 |
| 2021 | Research | $455,778 | 2 |
| 2020 | General | $325,446 | 246 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 32 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 33 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
2,558 general · 18 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.